REFERENCES
1. Luo Y, Zhang N, Ye J, et al. Unveiling lactylation modification: a new hope for cancer treatment. Biomed Pharmacother. 2025;184:117934.
2. Liu H, Pan M, Liu M, et al. Lactate: a rising star in tumors and inflammation. Front Immunol. 2024;15:1496390.
3. Lv X, Lv Y, Dai X. Lactate, histone lactylation and cancer hallmarks. Expert Rev Mol Med. 2023;25:e7.
4. He Y, Song T, Ning J, et al. Lactylation in cancer: mechanisms in tumour biology and therapeutic potentials. Clin Transl Med. 2024;14:e70070.
5. Yi D, Zhou K, Pan Y, Cai H, Huang P. The lactylation modification of proteins plays a critical role in tumor progression. Front Oncol. 2025;15:1530567.
6. Chen L, Huang L, Gu Y, Cang W, Sun P, Xiang Y. Lactate-lactylation hands between metabolic reprogramming and immunosuppression. Int J Mol Sci. 2022;23:11943.
7. Lv M, Huang Y, Chen Y, Ding K. Lactylation modification in cancer: mechanisms, functions, and therapeutic strategies. Exp Hematol Oncol. 2025;14:32.
8. Bilotta MT, Antignani A, Fitzgerald DJ. Managing the TME to improve the efficacy of cancer therapy. Front Immunol. 2022;13:954992.
9. Jin MZ, Jin WL. The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther. 2020;5:166.
10. Yu X, Yang J, Xu J, et al. Histone lactylation: from tumor lactate metabolism to epigenetic regulation. Int J Biol Sci. 2024;20:1833-54.
11. Dai M, Wang L, Yang J, et al. LDHA as a regulator of T cell fate and its mechanisms in disease. Biomed Pharmacother. 2023;158:114164.
12. Liu J, Zhang C, Zhang T, et al. Metabolic enzyme LDHA activates Rac1 GTPase as a noncanonical mechanism to promote cancer. Nat Metab. 2022;4:1830-46.
13. Feng Y, Xiong Y, Qiao T, Li X, Jia L, Han Y. Lactate dehydrogenase A: a key player in carcinogenesis and potential target in cancer therapy. Cancer Med. 2018;7:6124-36.
14. Chen H, Li Y, Li H, et al. NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance. Nature. 2024;631:663-9.
15. Tang Y, Gu S, Zhu L, Wu Y, Zhang W, Zhao C. LDHA: the obstacle to T cell responses against tumor. Front Oncol. 2022;12:1036477.
16. Chu YD, Cheng LC, Lim SN, Lai MW, Yeh CT, Lin WR. Aldolase B-driven lactagenesis and CEACAM6 activation promote cell renewal and chemoresistance in colorectal cancer through the Warburg effect. Cell Death Dis. 2023;14:660.
17. Duan W, Liu W, Xia S, et al. Warburg effect enhanced by AKR1B10 promotes acquired resistance to pemetrexed in lung cancer-derived brain metastasis. J Transl Med. 2023;21:547.
18. Wang R, Xu F, Yang Z, Cao J, Hu L, She Y. The mechanism of PFK-1 in the occurrence and development of bladder cancer by regulating ZEB1 lactylation. BMC Urol. 2024;24:59.
19. Li G, Wang D, Zhai Y, et al. Glycometabolic reprogramming-induced XRCC1 lactylation confers therapeutic resistance in ALDH1A3-overexpressing glioblastoma. Cell Metab. 2024;36:1696-710.e10.
20. Zong Z, Xie F, Wang S, et al. Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase that lactylates p53 and contributes to tumorigenesis. Cell. 2024;187:2375-92.e33.
21. Li H, Liu C, Li R, et al. AARS1 and AARS2 sense L-lactate to regulate cGAS as global lysine lactyltransferases. Nature. 2024;634:1229-37.
22. Ju J, Zhang H, Lin M, et al. The alanyl-tRNA synthetase AARS1 moonlights as a lactyltransferase to promote YAP signaling in gastric cancer. J Clin Invest. 2024;134:e174587.
23. Wu Y, Wang Y, Dong Y, Sun LV, Zheng Y. Lactate promotes H3K18 lactylation in human neuroectoderm differentiation. Cell Mol Life Sci. 2024;81:459.
24. Hou X, Ouyang J, Tang L, et al. KCNK1 promotes proliferation and metastasis of breast cancer cells by activating lactate dehydrogenase A (LDHA) and up-regulating H3K18 lactylation. PLoS Biol. 2024;22:e3002666.
25. Yang H, Yang S, He J, et al. Glucose transporter 3 (GLUT3) promotes lactylation modifications by regulating lactate dehydrogenase A (LDHA) in gastric cancer. Cancer Cell Int. 2023;23:303.
26. Chen M, Cen K, Song Y, et al. NUSAP1-LDHA-glycolysis-lactate feedforward loop promotes Warburg effect and metastasis in pancreatic ductal adenocarcinoma. Cancer Lett. 2023;567:216285.
27. Chen B, Deng Y, Hong Y, et al. Metabolic recoding of NSUN2-mediated m5C modification promotes the progression of colorectal cancer via the NSUN2/YBX1/m5C-ENO1 positive feedback loop. Adv Sci. 2024;11:e2309840.
28. Zhang R, Li L, Yu J. Lactate-induced IGF1R protein lactylation promotes proliferation and metabolic reprogramming of lung cancer cells. Open Life Sci. 2024;19:20220874.
29. Wang J, Yang P, Yu T, et al. Lactylation of PKM2 suppresses inflammatory metabolic adaptation in pro-inflammatory macrophages. Int J Biol Sci. 2022;18:6210-25.
30. Irizarry-Caro RA, McDaniel MM, Overcast GR, Jain VG, Troutman TD, Pasare C. TLR signaling adapter BCAP regulates inflammatory to reparatory macrophage transition by promoting histone lactylation. Proc Natl Acad Sci U S A. 2020;117:30628-38.
31. Huang J, Wang X, Li N, et al. YY1 lactylation aggravates autoimmune uveitis by enhancing microglial functions via inflammatory genes. Adv Sci. 2024;11:e2308031.
32. Li J, Chen X, Song S, et al. Hexokinase 2-mediated metabolic stress and inflammation burden of liver macrophages via histone lactylation in MASLD. Cell Rep. 2025;44:115350.
33. Su Z, Lan J, Wang Y, et al. Lactylation-driven ALKBH5 diminishes macrophage NLRP3 inflammasome activation in patients with G6PT deficiency. J Allergy Clin Immunol. 2025;155:1783-99.e8.
34. Zhu W, Zeng S, Zhu S, et al. Histone H2B lysine lactylation modulates the NF-κB response via KPNA2 during CSFV infection. Int J Biol Macromol. 2025;299:139973.
35. Liu C, Zheng J, Hao J, et al. Lactylation-related genes serve as potential markers for the diagnosis and immune infiltration in rheumatoid arthritis. Autoimmunity. 2025;58:2474217.
36. Colegio OR, Chu NQ, Szabo AL, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513:559-63.
37. Dai J, Lu X, Zhang C, et al. NNMT promotes acquired EGFR-TKI resistance by forming EGR1 and lactate-mediated double positive feedback loops in non-small cell lung cancer. Mol Cancer. 2025;24:79.
38. Zhang D, Tang Z, Huang H, et al. Metabolic regulation of gene expression by histone lactylation. Nature. 2019;574:575-80.
39. Xu X, Zhang DD, Kong P, et al. Sox10 escalates vascular inflammation by mediating vascular smooth muscle cell transdifferentiation and pyroptosis in neointimal hyperplasia. Cell Rep. 2023;42:112869.
40. Yang J, Luo L, Zhao C, et al. A positive feedback loop between inactive VHL-triggered histone lactylation and PDGFRβ signaling drives clear cell renal cell carcinoma progression. Int J Biol Sci. 2022;18:3470-83.
41. Kelly K, Cochran BH, Stiles CD, Leder P. Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell. 1983;35:603-10.
42. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol. 2007;27:7381-93.
43. Qing G, Skuli N, Mayes PA, et al. Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha. Cancer Res. 2010;70:10351-61.
44. Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015;5:378-89.
45. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7:11-20.
46. Wang F, Chen L, Kong D, et al. Canonical Wnt signaling promotes HSC glycolysis and liver fibrosis through an LDH-A/HIF-1α transcriptional complex. Hepatology. 2024;79:606-23.
47. Marín-Hernández A, Gallardo-Pérez JC, Ralph SJ, Rodríguez-Enríquez S, Moreno-Sánchez R. HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem. 2009;9:1084-101.
48. Xia P, Zhang H, Lu H, et al. METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression. Cancer Commun. 2023;43:338-64.
49. Miao Z, Zhao X, Liu X. Hypoxia induced β-catenin lactylation promotes the cell proliferation and stemness of colorectal cancer through the wnt signaling pathway. Exp Cell Res. 2023;422:113439.
50. Yan F, Teng Y, Li X, et al. Hypoxia promotes non-small cell lung cancer cell stemness, migration, and invasion via promoting glycolysis by lactylation of SOX9. Cancer Biol Ther. 2024;25:2304161.
51. Zang Y, Wang A, Zhang J, et al. Hypoxia promotes histone H3K9 lactylation to enhance LAMC2 transcription in esophageal squamous cell carcinoma. iScience. 2024;27:110188.
52. Li Q, Lin G, Zhang K, et al. Hypoxia exposure induces lactylation of Axin1 protein to promote glycolysis of esophageal carcinoma cells. Biochem Pharmacol. 2024;226:116415.
53. Fei X, Chen L, Gao J, et al. p53 lysine-lactylated modification contributes to lipopolysaccharide-induced proinflammatory activation in BV2 cell under hypoxic conditions. Neurochem Int. 2024;178:105794.
54. Dai E, Wang W, Li Y, Ye D, Li Y. Lactate and lactylation: behind the development of tumors. Cancer Lett. 2024;591:216896.
55. Chen F, Xue Y, Zhang W, et al. The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy. Cancer Metastasis Rev. 2024;43:1419-43.
56. Peng X, Gao Y, Liu J, et al. Mitochondria-derived vesicles: a promising and potential target for tumour therapy. Clin Transl Med. 2025;15:e70320.
57. Sun J, Feng Q, He Y, Wang M, Wu Y. Lactate activates CCL18 expression via H3K18 lactylation in macrophages to promote tumorigenesis of ovarian cancer. Acta Biochim Biophys Sin. 2024;56:1373-86.
58. Cheng Z, Huang H, Li M, Liang X, Tan Y, Chen Y. Lactylation-related gene signature effectively predicts prognosis and treatment responsiveness in hepatocellular carcinoma. Pharmaceuticals. 2023;16:644.
59. Chen J, Huang Z, Chen Y, et al. Lactate and lactylation in cancer. Signal Transduct Target Ther. 2025;10:38.
60. Sui Y, Shen Z, Wang Z, Feng J, Zhou G. Lactylation in cancer: metabolic mechanism and therapeutic strategies. Cell Death Discov. 2025;11:68.
62. Wang J, Wang Z, Wang Q, Li X, Guo Y. Ubiquitous protein lactylation in health and diseases. Cell Mol Biol Lett. 2024;29:23.
63. Zhao L, Qi H, Lv H, Liu W, Zhang R, Yang A. Lactylation in health and disease: physiological or pathological? Theranostics. 2025;15:1787-821.
64. Zhao Y, Jiang J, Zhou P, et al. H3K18 lactylation-mediated VCAM1 expression promotes gastric cancer progression and metastasis via AKT-mTOR-CXCL1 axis. Biochem Pharmacol. 2024;222:116120.
65. Duan Y, Zhan H, Wang Q, et al. Integrated lactylome characterization reveals the molecular dynamics of protein regulation in gastrointestinal cancers. Adv Sci. 2024;11:e2400227.
66. Liao J, Chen Z, Chang R, et al. CENPA functions as a transcriptional regulator to promote hepatocellular carcinoma progression via cooperating with YY1. Int J Biol Sci. 2023;19:5218-32.
67. Wu S, Li J, Zhan Y. H3K18 lactylation accelerates liver fibrosis progression through facilitating SOX9 transcription. Exp Cell Res. 2024;440:114135.
68. Hong H, Han H, Wang L, et al. ABCF1-K430-Lactylation promotes HCC malignant progression via transcriptional activation of HIF1 signaling pathway. Cell Death Differ. 2025;32:613-31.
69. Chen J, Zhao D, Wang Y, et al. Lactylated apolipoprotein C-II induces immunotherapy resistance by promoting extracellular lipolysis. Adv Sci. 2024;11:e2406333.
70. Sun T, Liu B, Li Y, et al. Oxamate enhances the efficacy of CAR-T therapy against glioblastoma via suppressing ectonucleotidases and CCR8 lactylation. J Exp Clin Cancer Res. 2023;42:253.
71. Qiu Q, Deng H, Song P, Liu Y, Zhang M. Lactylation in glioblastoma: a novel epigenetic modifier bridging epigenetic plasticity and metabolic reprogramming. Int J Mol Sci. 2025;26:3368.
72. Miao C, Zhao K, Zhu J, et al. Clinicopathological and prognostic role of long noncoding RNA Linc00152 in various human neoplasms: evidence from meta-analysis. Biomed Res Int. 2017;2017:6010721.
73. Tremblay CS, Saw J, Boyle JA, et al. STAT5 activation promotes progression and chemotherapy resistance in early T-cell precursor acute lymphoblastic leukemia. Blood. 2023;142:274-89.
74. Huang ZW, Zhang XN, Zhang L, et al. STAT5 promotes PD-L1 expression by facilitating histone lactylation to drive immunosuppression in acute myeloid leukemia. Signal Transduct Target Ther. 2023;8:391.
75. Li S, Yao W, Liu R, et al. Long non-coding RNA LINC00152 in cancer: roles, mechanisms, and chemotherapy and radiotherapy resistance. Front Oncol. 2022;12:960193.
76. Wang J, Liu Z, Xu Y, et al. Enterobacterial LPS-inducible LINC00152 is regulated by histone lactylation and promotes cancer cells invasion and migration. Front Cell Infect Microbiol. 2022;12:913815.
77. Xiong J, He J, Zhu J, et al. Lactylation-driven METTL3-mediated RNA m6A modification promotes immunosuppression of tumor-infiltrating myeloid cells. Mol Cell. 2022;82:1660-77.e10.
78. Yuan X, Wang Q, Zhao J, Xie H, Pu Z. The m6A methyltransferase METTL3 modifies Kcnk6 promoting on inflammation associated carcinogenesis is essential for colon homeostasis and defense system through histone lactylation dependent YTHDF2 binding. Int Rev Immunol. 2025;44:1-16.
79. Zhang Y, Jia S, Jiang WG. KIAA1199 and its biological role in human cancer and cancer cells (review). Oncol Rep. 2014;31:1503-8.
80. Zhai X, Wang W, Ma Y, et al. Serum KIAA1199 is an advanced-stage prognostic biomarker and metastatic oncogene in cholangiocarcinoma. Aging. 2020;12:23761-77.
81. Luo Y, Yang Z, Yu Y, Zhang P. HIF1α lactylation enhances KIAA1199 transcription to promote angiogenesis and vasculogenic mimicry in prostate cancer. Int J Biol Macromol. 2022;222:2225-43.
82. Zhou L, Zheng L, Hu K, et al. SUMOylation stabilizes hSSB1 and enhances the recruitment of NBS1 to DNA damage sites. Signal Transduct Target Ther. 2020;5:80.
83. Huang Y, Luo G, Peng K, et al. Lactylation stabilizes TFEB to elevate autophagy and lysosomal activity. J Cell Biol. 2024;223:e202308099.
85. Chen Y, Wu J, Zhai L, et al. Metabolic regulation of homologous recombination repair by MRE11 lactylation. Cell. 2024;187:294-311.e21.
86. Jia M, Yue X, Sun W, et al. ULK1-mediated metabolic reprogramming regulates Vps34 lipid kinase activity by its lactylation. Sci Adv. 2023;9:eadg4993.
87. Sun W, Jia M, Feng Y, Cheng X. Lactate is a bridge linking glycolysis and autophagy through lactylation. Autophagy. 2023;19:3240-1.
88. Rojas-Rivera D, Beltrán S, Muñoz-Carvajal F, et al. The autophagy protein RUBCNL/PACER represses RIPK1 kinase-dependent apoptosis and necroptosis. Autophagy. 2024;20:2444-59.
89. Li W, Zhou C, Yu L, et al. Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer. Autophagy. 2024;20:114-30.
90. Chun Y, Kim J. AMPK-mTOR signaling and cellular adaptations in hypoxia. Int J Mol Sci. 2021;22:9765.
91. Mele L, Del Vecchio V, Liccardo D, et al. The role of autophagy in resistance to targeted therapies. Cancer Treat Rev. 2020;88:102043.
92. Matoba K, Noda NN. Structural catalog of core Atg proteins opens new era of autophagy research. J Biochem. 2021;169:517-25.
93. Li XM, Yang Y, Jiang FQ, et al. Histone lactylation inhibits RARγ expression in macrophages to promote colorectal tumorigenesis through activation of TRAF6-IL-6-STAT3 signaling. Cell Rep. 2024;43:113688.
94. Gu J, Xu X, Li X, et al. Tumor-resident microbiota contributes to colorectal cancer liver metastasis by lactylation and immune modulation. Oncogene. 2024;43:2389-404.
95. Wang R, Li C, Cheng Z, et al. H3K9 lactylation in malignant cells facilitates CD8+ T cell dysfunction and poor immunotherapy response. Cell Rep. 2024;43:114686.
96. Li L, Li Z, Meng X, et al. Histone lactylation-derived LINC01127 promotes the self-renewal of glioblastoma stem cells via the cis-regulating the MAP4K4 to activate JNK pathway. Cancer Lett. 2023;579:216467.
97. Wei S, Zhang J, Zhao R, et al. Histone lactylation promotes malignant progression by facilitating USP39 expression to target PI3K/AKT/HIF-1α signal pathway in endometrial carcinoma. Cell Death Discov. 2024;10:121.
98. Xie B, Lin J, Chen X, et al. CircXRN2 suppresses tumor progression driven by histone lactylation through activating the Hippo pathway in human bladder cancer. Mol Cancer. 2023;22:151.
99. Deng J, Liao X. Lysine lactylation (Kla) might be a novel therapeutic target for breast cancer. BMC Med Genomics. 2023;16:283.
100. Gu J, Zhou J, Chen Q, et al. Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-β signaling in regulatory T cells. Cell Rep. 2022;39:110986.
101. Chaudagar K, Hieromnimon HM, Khurana R, et al. Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancer. Clin Cancer Res. 2023;29:1952-68.
102. Chaudagar K, Hieromnimon HM, Kelley A, et al. Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis. Clin Cancer Res. 2023;29:4930-40.
103. Husain Z, Seth P, Sukhatme VP. Tumor-derived lactate and myeloid-derived suppressor cells: linking metabolism to cancer immunology. Oncoimmunology. 2013;2:e26383.
104. Ugolini A, De Leo A, Yu X, et al. Functional reprogramming of neutrophils within the brain tumor microenvironment by hypoxia-driven histone lactylation. Cancer Discov. 2025;15:1270-96.
105. Brand A, Singer K, Koehl GE, et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 2016;24:657-71.
106. Zhao Z, Zhang Z, Cai Q, et al. Lactylation increases the stability of RBM15 to drives m6A modification in non-small-cell lung cancer cells. FASEB J. 2025;39:e70493.
107. Sun L, Zhang Y, Yang B, et al. Lactylation of METTL16 promotes cuproptosis via m6A-modification on FDX1 mRNA in gastric cancer. Nat Commun. 2023;14:6523.
108. Zhou C, Li W, Liang Z, et al. Mutant KRAS-activated circATXN7 fosters tumor immunoescape by sensitizing tumor-specific T cells to activation-induced cell death. Nat Commun. 2024;15:499.
109. Shim H, Dolde C, Lewis BC, et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A. 1997;94:6658-63.
110. Urbańska K, Orzechowski A. Unappreciated role of LDHA and LDHB to control apoptosis and autophagy in tumor cells. Int J Mol Sci. 2019;20:2085.
111. Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221:107753.
112. Suhail Y, Cain MP, Vanaja K, et al. Systems biology of cancer metastasis. Cell Syst. 2019;9:109-27.
113. Brown TP, Ganapathy V. Lactate/GPR81 signaling and proton motive force in cancer: role in angiogenesis, immune escape, nutrition, and Warburg phenomenon. Pharmacol Ther. 2020;206:107451.
114. Végran F, Boidot R, Michiels C, Sonveaux P, Feron O. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis. Cancer Res. 2011;71:2550-60.
115. Ye J, Gao X, Huang X, et al. Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma. Research. 2024;7:0387.
116. Liu J, Yan W, Han P, Tian D. The emerging role of KIAA1199 in cancer development and therapy. Biomed Pharmacother. 2021;138:111507.
117. Yu Y, Huang X, Liang C, Zhang P. Evodiamine impairs HIF1A histone lactylation to inhibit Sema3A-mediated angiogenesis and PD-L1 by inducing ferroptosis in prostate cancer. Eur J Pharmacol. 2023;957:176007.
118. Lu B, Chen S, Guan X, et al. Lactate accumulation induces H4K12la to activate super-enhancer-driven RAD23A expression and promote niraparib resistance in ovarian cancer. Mol Cancer. 2025;24:83.
119. He X, Li Y, Li J, et al. HDAC2-mediated METTL3 delactylation promotes DNA damage repair and chemotherapy resistance in triple-negative breast cancer. Adv Sci. 2025;12:e2413121.
120. Zhang XW, Li L, Liao M, et al. Thermal proteome profiling strategy identifies CNPY3 as a cellular target of gambogic acid for inducing prostate cancer pyroptosis. J Med Chem. 2024;67:10005-11.
121. Yue Q, Wang Z, Shen Y, et al. Histone H3K9 lactylation confers temozolomide resistance in glioblastoma via LUC7L2-mediated MLH1 intron retention. Adv Sci. 2024;11:e2309290.
122. Zhu M, Xiao Q, Cai X, et al. Predicting lymphoma prognosis using machine learning-based genes associated with lactylation. Transl Oncol. 2024;49:102102.
123. Li F, Zhang H, Huang Y, et al. Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer. Drug Resist Updat. 2024;73:101059.
124. Chen S, Li K, Guo J, et al. circNEIL3 inhibits tumor metastasis through recruiting the E3 ubiquitin ligase Nedd4L to degrade YBX1. Proc Natl Acad Sci U S A. 2023;120:e2215132120.
125. Huang J, Xie H, Li J, et al. Histone lactylation drives liver cancer metastasis by facilitating NSF1-mediated ferroptosis resistance after microwave ablation. Redox Biol. 2025;81:103553.
126. Deng J, Li Y, Yin L, et al. Histone lactylation enhances GCLC expression and thus promotes chemoresistance of colorectal cancer stem cells through inhibiting ferroptosis. Cell Death Dis. 2025;16:193.
127. Yang Z, Su W, Zhang Q, et al. Lactylation of HDAC1 confers resistance to ferroptosis in colorectal cancer. Adv Sci. 2025;12:e2408845.
128. Wu S, Liu M, Wang X, Wang S. The histone lactylation of AIM2 influences the suppression of ferroptosis by ACSL4 through STAT5B and promotes the progression of lung cancer. FASEB J. 2025;39:e70308.
129. He Y, Ji Z, Gong Y, et al. Numb/Parkin-directed mitochondrial fitness governs cancer cell fate via metabolic regulation of histone lactylation. Cell Rep. 2023;42:112033.
130. Jin J, Bai L, Wang D, et al. SIRT3-dependent delactylation of cyclin E2 prevents hepatocellular carcinoma growth. EMBO Rep. 2023;24:e56052.
131. Pan L, Feng F, Wu J, et al. Demethylzeylasteral targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells. Pharmacol Res. 2022;181:106270.
132. Liberti MV, Locasale JW. Histone lactylation: a new role for glucose metabolism. Trends Biochem Sci. 2020;45:179-82.
133. Jiang J, Huang D, Jiang Y, et al. Lactate modulates cellular metabolism through histone lactylation-mediated gene expression in non-small cell lung cancer. Front Oncol. 2021;11:647559.
134. Yu J, Chai P, Xie M, et al. Histone lactylation drives oncogenesis by facilitating m6A reader protein YTHDF2 expression in ocular melanoma. Genome Biol. 2021;22:85.
135. Le A, Cooper CR, Gouw AM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A. 2010;107:2037-42.
136. Boudreau A, Purkey HE, Hitz A, et al. Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition. Nat Chem Biol. 2016;12:779-86.
137. Gupta VK, Sharma NS, Durden B, et al. Hypoxia-driven oncometabolite L-2HG maintains stemness-differentiation balance and facilitates immune evasion in pancreatic cancer. Cancer Res. 2021;81:4001-13.
138. Qi CL, Huang ML, Zou Y, et al. The IRF2/CENP-N/AKT signaling axis promotes proliferation, cell cycling and apoptosis resistance in nasopharyngeal carcinoma cells by increasing aerobic glycolysis. J Exp Clin Cancer Res. 2021;40:390.
139. Serganova I, Cohen IJ, Vemuri K, et al. LDH-A regulates the tumor microenvironment via HIF-signaling and modulates the immune response. PLoS One. 2018;13:e0203965.
140. Liu R, Ren X, Park YE, et al. Nuclear GTPSCS functions as a lactyl-CoA synthetase to promote histone lactylation and gliomagenesis. Cell Metab. 2025;37:377-94.e9.
141. Yang L, Niu K, Wang J, et al. Nucleolin lactylation contributes to intrahepatic cholangiocarcinoma pathogenesis via RNA splicing regulation of MADD. J Hepatol. 2024;81:651-66.
142. Li F, Si W, Xia L, et al. Positive feedback regulation between glycolysis and histone lactylation drives oncogenesis in pancreatic ductal adenocarcinoma. Mol Cancer. 2024;23:90.
143. Welti J, Sharp A, Brooks N, et al; SU2C/PCF International Prostate Cancer Dream Team. Targeting the p300/CBP axis in lethal prostate cancer. Cancer Discov. 2021;11:1118-37.
144. Lasko LM, Jakob CG, Edalji RP, et al. Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. Nature. 2018;558:E1.
145. Zeng Q, Wang K, Zhao Y, Ma Q, Chen Z, Huang W. Effects of the acetyltransferase p300 on tumour regulation from the novel perspective of posttranslational protein modification. Biomolecules. 2023;13:417.
146. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25:4633-46.
147. Xu H, Li L, Wang S, et al. Royal jelly acid suppresses hepatocellular carcinoma tumorigenicity by inhibiting H3 histone lactylation at H3K9la and H3K14la sites. Phytomedicine. 2023;118:154940.
148. Guo Z, Tang Y, Wang S, et al. Natural product fargesin interferes with H3 histone lactylation via targeting PKM2 to inhibit non-small cell lung cancer tumorigenesis. Biofactors. 2024;50:592-607.
149. Heuser C, Renner K, Kreutz M, Gattinoni L. Targeting lactate metabolism for cancer immunotherapy - a matter of precision. Semin Cancer Biol. 2023;88:32-45.
150. Ersahin T, Tuncbag N, Cetin-Atalay R. The PI3K/AKT/mTOR interactive pathway. Mol Biosyst. 2015;11:1946-54.
151. Peng Y, Wang Y, Zhou C, Mei W, Zeng C. PI3K/Akt/mTOR pathway and its role in cancer therapeutics: are we making headway? Front Oncol. 2022;12:819128.
152. Kuo CT, Chen CL, Li CC, et al. Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models. Sci Rep. 2019;9:10898.
153. Gao F, Li R, Wei PF, et al. Synergistic anticancer effects of everolimus (RAD001) and Rhein on gastric cancer cells via phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway. Bioengineered. 2022;13:6332-42.
154. Ciołczyk-Wierzbicka D, Gil D, Zarzycka M, Laidler P. mTOR inhibitor everolimus reduces invasiveness of melanoma cells. Hum Cell. 2020;33:88-97.
155. Kobayashi H. Everolimus-eluting stent-induced pneumonitis. Am J Respir Crit Care Med. 2022;205:12-3.
156. Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15:234-48.
157. Le Floch R, Chiche J, Marchiq I, et al. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc Natl Acad Sci U S A. 2011;108:16663-8.
158. Doherty JR, Yang C, Scott KE, et al. Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis. Cancer Res. 2014;74:908-20.
159. Garcia CK, Goldstein JL, Pathak RK, Anderson RG, Brown MS. Molecular characterization of a membrane transporter for lactate, pyruvate, and other monocarboxylates: implications for the Cori cycle. Cell. 1994;76:865-73.
160. Qian Y, Galan-Cobo A, Guijarro I, et al. MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma. Cancer Cell. 2023;41:1363-80.e7.
161. Zhao Y, Li M, Yao X, et al. HCAR1/MCT1 regulates tumor ferroptosis through the lactate-mediated AMPK-SCD1 activity and its therapeutic implications. Cell Rep. 2020;33:108487.
162. Beloueche-Babari M, Casals Galobart T, Delgado-Goni T, et al. Monocarboxylate transporter 1 blockade with AZD3965 inhibits lipid biosynthesis and increases tumour immune cell infiltration. Br J Cancer. 2020;122:895-903.
163. Cao Z, Xu D, Harding J, et al. Lactate oxidase nanocapsules boost T cell immunity and efficacy of cancer immunotherapy. Sci Transl Med. 2023;15:eadd2712.
164. Zhao J, Tian Z, Zhao S, et al. Insights into the effect of catalytic intratumoral lactate depletion on metabolic reprogramming and immune activation for antitumoral activity. Adv Sci. 2023;10:e2204808.
165. Ding B, Zheng P, Tan J, et al. Sodium bicarbonate nanoparticles for amplified cancer immunotherapy by inducing pyroptosis and regulating lactic acid metabolism. Angew Chem Int Ed Engl. 2023;62:e202307706.
166. Wang X, Zhao Y, Shi L, et al. Tumor-targeted disruption of lactate transport with reactivity-reversible nanocatalysts to amplify oxidative damage. Small. 2021;17:e2100130.
167. Wu S, Xu L, He C, et al. Lactate efflux inhibition by syrosingopine/LOD co-loaded nanozyme for synergetic self-replenishing catalytic cancer therapy and immune microenvironment remodeling. Adv Sci. 2023;10:e2300686.
168. Li K, Lin C, He Y, et al. Engineering of cascade-responsive nanoplatform to inhibit lactate efflux for enhanced tumor chemo-immunotherapy. ACS Nano. 2020;14:14164-80.
169. Li HM, Guo HL, Xu C, et al. Inhibition of glycolysis by targeting lactate dehydrogenase A facilitates hyaluronan synthase 2 synthesis in synovial fibroblasts of temporomandibular joint osteoarthritis. Bone. 2020;141:115584.
170. Bader A, Tuccinardi T, Granchi C, et al. Phenylpropanoids and flavonoids from Phlomis kurdica as inhibitors of human lactate dehydrogenase. Phytochemistry. 2015;116:262-8.
171. Granchi C, Roy S, Giacomelli C, et al. Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells. J Med Chem. 2011;54:1599-612.
172. Yang X, Liu Y, Wang P, et al. Targeting PDHK1 by DCA to restore NK cell function in hepatocellular carcinoma. Mol Cancer Ther. 2024;23:1731-42.
173. Liu Z, Zheng J, Ding T, et al. HIF-1α protects nucleus pulposus cells from oxidative stress-induced mitochondrial impairment through PDK-1. Free Radic Biol Med. 2024;224:39-49.
174. Xian H, Wang Y, Bao X, et al. Hexokinase inhibitor 2-deoxyglucose coordinates citrullination of vimentin and apoptosis of fibroblast-like synoviocytes by inhibiting HK2/mTORC1-induced autophagy. Int Immunopharmacol. 2023;114:109556.
175. Pajak B, Siwiak E, Sołtyka M, et al. 2-Deoxy-d-glucose and its analogs: from diagnostic to therapeutic agents. Int J Mol Sci. 2019;21:234.
176. Hasskarl J. Everolimus. In: Martens UM, editor. Small molecules in oncology. Cham: Springer International Publishing; 2018. pp. 101-23.
177. Chen W, Tan Q, Guo M, et al. Tumor cell-derived microparticles packaging monocarboxylate transporter4 inhibitor fluvastatin suppress lung adenocarcinoma via tumor microenvironment remodeling and improve chemotherapy. Chem Eng J. 2023;451:138972.
178. Fan H, Yang F, Xiao Z, et al. Lactylation: novel epigenetic regulatory and therapeutic opportunities. Am J Physiol Endocrinol Metab. 2023;324:E330-8.
179. Li H, Sun L, Gao P, Hu H. Lactylation in cancer: current understanding and challenges. Cancer Cell. 2024;42:1803-7.
180. Chen AN, Luo Y, Yang YH, et al. Lactylation, a novel metabolic reprogramming code: current status and prospects. Front Immunol. 2021;12:688910.
181. Zhang Q, Luo Y, Qian B, et al. A systematic pan-cancer analysis identifies LDHA as a novel predictor for immunological, prognostic, and immunotherapy resistance. Aging. 2024;16:8000-18.
182. Chen Q, Yang B, Liu X, Zhang XD, Zhang L, Liu T. Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents. Theranostics. 2022;12:4935-48.
